Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 1.00 |
| ▸ | IDH2 | P48735 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Crelosidenib SCHEMBL20289768 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL29765374 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20270338 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20270341 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL20271764 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Crelosidenib SCHEMBL21799142 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170447 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170446 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL24170089 | 0.97 | IDH1 (0.94) | IDH1IDH2 | |
| SCHEMBL25227127 | 0.97 | IDH1 (0.94) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337217-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | Eli Lilly and Company (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2023141087-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-07-27 | — | — | WO | claimed |
| EP-4181927-A1 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | Eli Lilly and Company (US) | 2023-05-24 | — | — | EP | claimed |
| EP-4125917-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR AND A BCL-2 INHIBITOR | Eli Lilly and Company (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4125915-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | Eli Lilly and Company (US) | 2023-02-08 | — | — | EP | claimed |
| EP-4125916-A1 | METHOD FOR TREATING IDH1 INHIBITOR-RESISTANT SUBJECTS | ELI LILLY AND COMPANY (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2022261279-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | ELI LILLY AND COMPANY (US) | 2022-12-15 | — | — | WO | claimed |
| CN-115443137-A | Combination therapy using a mutant IDH inhibitor and a BCL-2 inhibitor | 伊莱利利公司 | 2022-12-06 | — | — | CN | claimed |
| CN-115335060-A | Combination therapy with mutant IDH inhibitors | 伊莱利利公司 | 2022-11-11 | — | — | CN | claimed |
| CN-115335059-A | Methods for treating IDH1 inhibitor resistant subjects | 伊莱利利公司 | 2022-11-11 | — | — | CN | claimed |
| CN-115109075-A | Mutant IDH1 and IDH2 inhibitors | 伊莱利利公司 | 2022-09-27 | — | — | CN | claimed |
| CN-110072867-B | 7-phenylethylamino-4H-pyrimido [4,5-D ] [1,3] oxazin-2-one compounds as inhibitors of mutant IDH1 and IDH2 | 伊莱利利公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2022020281-A1 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | ELI LILLY AND COMPANY (US) | 2022-01-27 | — | — | WO | claimed |
| EP-4384273-A1 | SOLID FORMS OF 7-[[(1S)-1-[4-[(1S)-2-CYCLOPROPYL-1-(4-PROP-2- ENOYLPIPERAZIN-1-YL)ETHYL]PHENYL]ETHYL]AMINO]-1-ETHYL-4H- PYRIMIDO[4,5-D] [1,3]OXAZIN-2-ONE | Eli Lilly and Company (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4337217-A1 | METHOD FOR TREATING IDH INHIBITOR-RESISTANT SUBJECTS | Eli Lilly and Company (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023141087-A1 | COMBINATION THERAPY WITH A MUTANT IDH INHIBITOR | ELI LILLY AND COMPANY (US) | 2023-07-27 | — | — | WO | disclosed |
| CN-115335060-A | Combination therapy with mutant IDH inhibitors | 伊莱利利公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115109075-A | Mutant IDH1 and IDH2 inhibitors | 伊莱利利公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-110072867-B | 7-phenylethylamino-4H-pyrimido [4,5-D ] [1,3] oxazin-2-one compounds as inhibitors of mutant IDH1 and IDH2 | 伊莱利利公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022020281-A1 | COMBINATION THERAPY WITH A MUTANT IDH1 INHIBITOR, A DEOXYADENOSINE ANALOG, AND A PLATINUM AGENT | ELI LILLY AND COMPANY (US) | 2022-01-27 | — | — | WO | disclosed |